Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease (LINC-4)

• ClinicalTrials.gov Identifier: NCT02697734
• Recruitment Status: Completed
• First Posted: March 3, 2016
• Results First Posted: October 19, 2021
• Last Update Posted: November 1, 2021
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.

Condition or disease	Intervention/treatment	Phase
Cushing's Disease	Drug: osilodrostat; Drug: osilodrostat Placebo	Phase 3

Detailed Description:

The study LCI699C2302 (LINC-4) is a multi-center, randomized, double-blind study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease.

Enrolled patients were initially randomized to either osilodrostat or placebo, in a 2:1 ratio, for a 12-week double-blind period (Period 1). Randomization was stratified by history of pituitary radiation. After Week 12, all patients received open-label osilodrostat until the end of the Core phase at Week 48 (Period 2).

After Week 48, patients could join an optional 48 week extension period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 73 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
• Actual Study Start Date: October 3, 2016
• Actual Primary Completion Date: June 19, 2019
• Actual Study Completion Date: December 31, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: osilodrostat Group; Participants in this arm were randomized to receive the study drug, osilodrostat followed after Week 12 by open-label osilodrostat at the starting dose (with a second dose titration)	Drug: osilodrostat; In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.; Other Name: LCI699
Placebo Comparator: osilodrostat Placebo Group; Participants in this arm were randomized to receive osilodrostat placebo followed after Week 12 by open-label osilodrostat at the starting dose (with a dose titration)	Drug: osilodrostat Placebo; Matching Placebo in the form of filmcoated tablets for oral administration

Outcome Measures

Primary Outcome Measures :

1. Percentage of Randomized Participants With a Complete Response [ Time Frame: at Week 12 ]

   A complete responder at week 12 is defined as a participant who had a mean urine free cortisol ≤ upper limit of normal (mUFC ≤ ULN) at Week 12.

   Participants who had a missing mUFC assessment at Week 12 were counted as non-responders for the primary endpoint.

Secondary Outcome Measures :

1. Percentage of Participants With mUFC ≤ ULN at Week 36 [ Time Frame: At Week 36 ]
   The complete response rate in both arms combined at Week 36. A complete responder at Week 36 is defined as a participant who had mean urine free cortisol <= upper limit of normal (mUFC <= ULN) at Week 36. Participants with missing mUFC at Week 36 were counted as non-responders.
2. Change From Baseline in mUFC [ Time Frame: Baseline, weeks 2,5,8,12,14,17,20,23,26,29,32,36,40,48,60,72,84,96 ]
   To assess the change in mean urinary free cortisol (mUFC) from baseline by treatment arm.
3. Time-to-first Control of mUFC - Number (%) of Participants With mUFC <=ULN [ Time Frame: up to 12 weeks ]

   To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was ≤ ULN before completion/discontinuation of placebo-controlled period.

   Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.

4. Time-to-first Control of mUFC - Median Time to First Controlled mUFC Response [ Time Frame: up to 12 weeks ]

   To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was ≤ ULN before completion/discontinuation of placebo-controlled period.

   Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.

   The median time-to-first control and corresponding two-sided 95% Confidence Interval were calculated using Kaplan-Meier methodology of Brookmeyer and Crowley (1982).

5. Time-to-first Control of mUFC - % Event Probability Estimates [ Time Frame: up to 12 weeks ]

   To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was ≤ ULN before completion/discontinuation of placebo-controlled period.

   Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.

   % Event probability estimate is the estimated probability that a participant will have an event prior to the specified time point. % Event probability estimates are obtained from the Kaplan-Meier survival estimates for all treatment groups; Greenwood formula is used for Confidence Interval (CI) of Kaplan-Meier (KM) estimates.

6. Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (≤ ULN) to the First mUFC > 1.3 x ULN - Number (%) of Participants [ Time Frame: up to 48 weeks ]
   To assess time-to-escape from the first collection of normal mUFC (≤ ULN) to the first mUFC > 1.3 x ULN on two consecutive visits on the highest tolerated dose of osilodrostat and not related to a dose interruption or dose reduction due to safety reasons. Escape will not be assessed for participants during the first 26 weeks.
7. Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (≤ ULN) to the First mUFC > 1.3 x ULN - Median Time to Escape From Normal mUFC [ Time Frame: from week 26 to week 48 ]

   To assess time-to-escape from the first collection of normal mUFC (≤ ULN) to the first mUFC > 1.3 x ULN on two consecutive visits on the highest tolerated dose of osilodrostat and not related to a dose interruption or dose reduction due to safety reasons. Escape will not be assessed for participants during the first 26 weeks.

   The median time-to-escape and corresponding two-sided 95% Confidence Interval were calculated using Kaplan-Meier methodology of Brookmeyer and Crowley (1982).

8. Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (≤ ULN) to the First mUFC > 1.3 x ULN - % Event Probability Estimates [ Time Frame: week 26 and week 36 ]

   Escape is defined as the first loss of control of urinary free cortisol (UFC) that meets all of the following criteria: 1. prior normalization of UFC has occurred (median urinary free cortisol (mUFC)≤ upper limit of normal (ULN)); 2. patient reached the highest tolerated dose of osilodrostat; 3. 2 consecutive mUFC (collected at scheduled visits) were above 1.3x ULN; 4. the loss of control of UFC is not related to a dose interruption or dose reduction due to safety reasons; 5. happened beyond Week 26 when the patients have a chance to be treated with doses as high as 30 mg bid.

   • Event probability estimate is the estimated probability that a participant will have an event prior to the specified time point.
   • Event probability estimates are obtained from the Kaplan-Meier survival estimates for all treatment groups; Greenwood formula is used for CI of KM estimates.
9. Change From Baseline in Bone Mineral Density (BMD) by Dual-energy X-ray Absorptiometry (DXA) Scan at the Femoral Neck, Hip and Spinal Cord - QC Corrected [ Time Frame: Baseline, week 48 ]
   The change from baseline in bone mineral density at the femoral neck, hip and spinal cord at Week 48 by treatment arm - QC corrected. An increase in bone mineral density is indicative of an improvement.
10. Change From Baseline in Bone Mineral Density (BMD) T-score by Dual-energy X-ray Absorptiometry (DXA) Scan at the Femoral Neck, Hip and Spinal Cord - QC Corrected [ Time Frame: Baseline, week 48 ]
    The change from baseline in bone mineral density at the femoral neck, hip and spinal cord at Week 48 by treatment arm - QC corrected. An increase in bone mineral density is indicative of an improvement. T-score is the number of standard deviations above or below the mean for a healthy 30-year-old adult of the same sex and ethnicity as the patient. The WHO criteria are: Normal is a T-score of -1.0 or higher"
11. Patients With a Complete Response (mUFC ≤ ULN) or a Partial Response (mUFC Decrease ≥ 50% From Baseline and >ULN) at Week 12, 36 and 48 [ Time Frame: baseline, week 12, 36 and 48 ]
    Overall response rate defined as percentage of complete responders (mUFC ≤ ULN) plus partial responders (≥ 50% reduction in mUFC from baseline and >ULN) at week 12, 36, 48 by treatment arms for all patients.
12. Change in Fasting Plasma Glucose [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in fasting plasma glucose at Week 12, Week 36, and Week 48 by treatment arm
13. Change in Hemoglobin A1C [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Hemoglobin A1C (%) at Week 12, Week 36, and Week 48 by treatment arm
14. Change in Cholesterol [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm
15. Change in LDL Cholesterol [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in LDL Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm
16. Change in HDL Cholesterol [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in HDL Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm
17. Change in Triglyceride [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Triglyceride (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm
18. Change in Standing Systolic Blood Pressure [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Standing Systolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm
19. Change in Supine Systolic Blood Pressure [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Supine Systolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm
20. Change in Standing Diastolic Blood Pressure [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Standing Diastolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm
21. Change in Supine Diastolic Blood Pressure [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Supine Diastolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm
22. Change in Weight [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Weight (kg) at Week 12, Week 36, and Week 48 by treatment arm
23. Change in Waist Circumference [ Time Frame: Baseline, weeks 12, 36, and 48 ]
    Change from baseline in Waist Circumference (cm) at Week 12, Week 36, and Week 48 by treatment arm
24. Change From Baseline to Week 12, Week 36, and Week 48 in Clinical Signs of Cushing's Disease [ Time Frame: baseline, Week 12, Week 36 and Week 48 ]
    Change from baseline to Week 12, Week 36, and Week 48 in each of the following clinical signs of Cushing's disease, captured by: a semi-quantitative Likert scale for facial rubor, striae, supraclavicular fat pad, dorsal fat pad, proximal muscle wasting (atrophy), central (abdominal) obesity, and ecchymoses (bruises) by randomized treatment arm. The number/proportion of participants with an improvement or no change compared to baseline are reported
25. Change From Baseline in Standardized Health Related Quality of Life Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]

    The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').

    The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.

26. Change From Baseline in Standardized Psychosocial Issues Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]

    The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').

    The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.

27. Change From Baseline in Standardized Physical Problems Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]

    The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').

    The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.

28. Change From Baseline in EQ-5D-5L Utility Index [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]

    EQ-5D-5L Utility Index:

    The EQ-5D-5L questionnaire is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L measures 5 items on mobility, self-care, usual activities, pain/discomfort, anxiety/depression, measured on 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A utility index can be computed from the EQ 5D-5L descriptive system with utility scores ranging from -0.281 (worst imaginable health state) to 1 (best imaginable health state), with -0.281 representing an "unconscious" health state. A single index value is analyzed for the EQ-5D-5L score. An increase from baseline in the EQ-ED-5L utility index is indicative of an improvement.

29. Change From Baseline in EQ-5D VAS [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]
    The EQ-5D-5L also includes a 20 cm vertical, VAS (visual analogue scale) with a scale of 0-100, with endpoints labeled 100='the best health you can imagine' and 0='the worst health you can imagine'. A single index value is analyzed for the EQ-5D-5L VAS score. An increase from baseline in the EQ-ED-5L VAS is indicative of an improvement.
30. Change From Baseline in Beck Depression Inventory-II - Total Score Derived [ Time Frame: Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48. ]
    The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical and normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. A global score ranges from 0 to 63 and is calculated with a higher score representing a greater level of depression. The following scoring guidelines for interpretation of BDI-II have been suggested (Smarr, 2011): Minimal range =0-13, Mild depression =14-19, Moderate depression =20-28 and Severe depression = 29-63. A reduction from baseline in BDI-II is indicative of an improvement.
31. Change From Baseline in Serum Cortisol [ Time Frame: Baseline, Week 12, Week 36, Week 48 ]
    Change from baseline in serum cortisol
32. Change From Baseline in Late Night Saliva Cortisol [ Time Frame: Baseline, Week 12, Week 36, Week 48 ]
    Change from baseline in late night saliva cortisol (nmol/L)
33. Change From Baseline in Morning Saliva Cortisol [ Time Frame: Baseline, Week 12, Week 36, Week 48 ]
    Change from baseline in morning saliva cortisol (nmol/L)
34. Change From Baseline in Hair Cortisol Levels [ Time Frame: Baseline, Week 26, Week 48 ]
    Change from baseline in hair cortisol levels
35. Plasma Osilodrostat Concentrations (ng/mL) [ Time Frame: pre-dose and 1-2hrs post dose at weeks 1, 2, 5, 8, 12, 14, 20, 26 ]
    Plasma osilodrostat concentrations (ng/mL)

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key inclusion criteria:

• Confirmed Cushing's Disease (CD) that is persistent or recurrent as evidenced by all of the following criteria being met (i.e., a, b and c):

  1. mUFC > 1.3 x ULN (Mean of three 24-hour urine samples collected preferably on 3 consecutive days, during screening after washout of prior medical therapy for CD (if applicable), confirmed by the central laboratory and available before Day 1), with ≥2 of the individual UFC values being > 1.3 x ULN.
  2. Morning plasma Adrenocorticotropic hormone (ACTH) above Lower Limit of Normal

  3. Confirmation (based on medical history) of pituitary source of excess

     ACTH as defined by any one or more of the following three criteria:

  i. Histopathologic confirmation of an ACTH-staining adenoma in patients who have had prior pituitary surgery. OR ii. Magnetic resonance imaging (MRI) confirmation of pituitary adenoma > 6 mm OR iii. Bilateral inferior petrosal sinus sampling (BIPSS) with either corticotropic-releasing hormone (CRH) or desmopressin (DDAVP) stimulation for patients with a tumor ≤ 6mm. The criteria for a confirmatory BIPSS test are any of the following: Pre-dose central to peripheral ACTH gradient > 2; Post-dose central to peripheral ACTH gradient > 3 after either CRH or DDAVP stimulation

• Patients that received glucocorticoid replacement therapy must have discontinued such therapy for at least seven days or 5 half-lives prior to screening, whichever is longer.
• Patients with de novo CD can be included only if they are not considered candidates for surgery (e.g., poor surgical candidates due to co-morbidities, inoperable tumors, patients who refuse to have surgical treatment, or surgical treatment is not available).

Key exclusion criteria:

• Patients with pseudo-Cushing's syndrome. This may be diagnosed by a normal late night salivary cortisol value collected during the screening period and after washout of prior CD medication.
• Patients with risk factors for QT corrected (QTc) prolongation or Torsade de Pointes, including:

patients with a baseline QT corrected (Fridericia QT formula) (QTcF) > 450 ms for males and QTcF > 460 ms for females; personal or family history of long QT syndrome; concomitant medications known to prolong the QT interval; patients with hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected before pre-dose Day 1.

• Patients likely to require adrenalectomy, pituitary surgery, or radiation therapy during the placebo-controlled period (Weeks 1-12) for the treatment of severe hypercortisolism or pituitary tumor growth causing compression of the optic chiasm.
• Patients with compression of the optic chiasm due to a macroadenoma or patients at high risk of compression of the optic chiasm (tumor within 2 mm of optic chiasm).
• Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e. Carney Complex, McCune-Albright syndrome, MEN-1, AIP).
• Patients with Cushing's syndrome due to ectopic ACTH secretion or ACTH independent (adrenal) Cushing's syndrome. Pregnant or nursing (lactating) women. 8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after completion of dosing. Highly effective contraception methods include: A. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. B. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study drug. In case of bilateral oophorectomy, documentation is required (e.g. operative report, pelvic ultrasound or other reliable imaging method). C. Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.

D. Combination of any two of the following (a+b or a+c, or b+c):

1. Use of oral*, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. *In the case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study drug. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential.

Contacts and Locations

Locations

United States, Colorado

University of Colorado Endocrinology Clinical Trials Unit

Aurora, Colorado, United States, 80045

United States, Michigan

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States, 48109

United States, New York

Columbia University Medical Center New York Presbyterian Neuroendocrine Unit

New York, New York, United States, 10032

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, Oregon

Oregon Health and Science University SC LCI699C2301

Portland, Oregon, United States, 97239

United States, Pennsylvania

University of Pennsylvania Medical Center University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Belgium

Novartis Investigative Site

Leuven, Belgium, 3000

Brazil

Novartis Investigative Site

Fortaleza, CE, Brazil, 60430-275

Novartis Investigative Site

Rio de Janeiro, RJ, Brazil, 21941-590

Novartis Investigative Site

Sao Paulo, SP, Brazil, 04039 004

Novartis Investigative Site

Sao Paulo, SP, Brazil, 05403 000

Canada, Nova Scotia

Novartis Investigative Site

Halifax, Nova Scotia, Canada, B3H 1V7

Canada, Quebec

Novartis Investigative Site

Montreal, Quebec, Canada, H2W 1T8

Novartis Investigative Site

Sherbrooke, Quebec, Canada, J1H 5N4

China, Sichuan

Novartis Investigative Site

Chengdu, Sichuan, China, 610041

China

Novartis Investigative Site

Beijing, China, 100034

Novartis Investigative Site

Beijing, China, 100730

Novartis Investigative Site

Guang Zhou, China, 510080

Costa Rica

Novartis Investigative Site

San Pedro, San Jose, Costa Rica, Costa Rica, 1406 1200

Greece

Novartis Investigative Site

Athens, Greece, 106 76

Poland

Novartis Investigative Site

Warszawa, Mazowieckie, Poland, 04-305

Novartis Investigative Site

Krakow, Poland, 31-501

Novartis Investigative Site

Warszawa, Poland, 03 242

Portugal

Novartis Investigative Site

Porto, Portugal, 4200-319

Russian Federation

Novartis Investigative Site

Moscow, Russian Federation, 117036

Spain

Novartis Investigative Site

Malaga, Andalucia, Spain, 29009

Novartis Investigative Site

Sevilla, Andalucia, Spain, 41013

Novartis Investigative Site

Alzira, Comunidad Valenciana, Spain, 46600

Novartis Investigative Site

Valencia, Comunidad Valenciana, Spain, 46026

Novartis Investigative Site

La Coruna, Galicia, Spain, 15006

Novartis Investigative Site

Madrid, Spain, 28009

Switzerland

Novartis Investigative Site

Luzern, Switzerland, 6000

Thailand

Novartis Investigative Site

Bangkok, THA, Thailand, 10330

Novartis Investigative Site

Bangkok, Thailand, 10700

Turkey

Novartis Investigative Site

Istanbul, Turkey, 34890

Novartis Investigative Site

Kocaeli, Turkey, 41380

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):

Study Protocol  [PDF] December 20, 2019

Statistical Analysis Plan  [PDF] December 1, 2020

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2882-e2895. doi: 10.1210/clinem/dgac178.

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT02697734
• Other Study ID Numbers: CLCI699C2302
• First Posted: March 3, 2016
• Results First Posted: October 19, 2021
• Last Update Posted: November 1, 2021
• Last Verified: October 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

• URL: https://www.clinicalstudydatarequest.com

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Cushing's disease; LCI699; osilodrostat; Pituitary Gland; Adrenocorticotropic; Hormone; ACTH; UFC

Additional relevant MeSH terms:

ACTH-Secreting Pituitary Adenoma; Pituitary ACTH Hypersecretion; Hyperpituitarism; Pituitary Diseases; Hypothalamic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Endocrine System Diseases; Adenoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Pituitary Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site